Healthcare is the clearest place money is moving, and UnitedHealth is the preferred name here. It beat earnings and raised its 2026 profit forecast. x.com 

UnitedHealth's earnings visibility, unusually high dividend yield and resumed buybacks make paying under 16x forward earnings not look terrible. Still reasonably confident it is a good place to hide for long-term capital: Hemsley keeps clearing the bar, and UnitedHealth has beaten and raised guidance for three straight quarters. Further derisking remains a risk. x.com  x.com  x.com 

UnitedHealth's rebound still has a Medicaid problem because care costs are outpacing state funding. Q3 operating profit rose to $6.6bn from $4.3bn a year earlier, but Medicaid is still expected to lose money in 2026. x.com 

UnitedHealth's collapse was driven more by fear than fundamentals, making it one of the biggest opportunities in years, reminiscent of Meta in 2022. Fraud accusations led nowhere as the DOJ dropped its investigation, and peers Humana and CVS recovered from the same cost underestimation and beat later. With over $420B in revenue and deep ties to US employers, UnitedHealth is too big to fail and could survive even a fine. That same logic pointed to Berkshire being the undisclosed buyer. x.com 

UnitedHealth should outperform through year-end on midterm-year seasonality and as a defensive leader if markets weaken. Over the last 20 years, healthcare has generally done well from July through December in midterm years, and if the S&P 500 rolls into a bear market, investors should rotate into defensives led by UNH. The bull case also rests on AI and GLP-1 use lowering the medical cost ratio and institutions returning to healthcare. The war has made everything more volatile. x.com 

UnitedHealth's debt has to come down to a manageable $20-30B, which would also cut interest expense, and the institutions, TV contributors and big retail accounts pumping it like the next Nvidia are ignoring that. Health insurance is not going away, but the numbers matter more than the hype. x.com 

UnitedHealth collects ever-rising US healthcare spending, and its stock has stopped falling. Family plan costs rose 249% in two decades toward $24,000, US spending nears $10,000 a person, and the over-65 population is set to double to two billion by 2050. After earnings fell 59% and 69% in back-to-back quarters and the stock dropped from 606 to 248, it based near 250 for a year, a Weinstein Stage 1, then reclaimed its moving average and pushed above 400. x.com  x.com  x.com  x.com 

AI's application layer remains the long-term bet: after 24 months in infrastructure on obvious earnings, capital must now move to the layer that produces durable economic value. Tempus AI's edge is proprietary data, which stays scarce as raw intelligence gets cheaper. Eli Lilly's LillyPod pairs 1,000 Blackwell GPUs with decades of clinical data, an underrated moat. Lemonade's tech yields cost, price and growth edges. Coinbase provides the stablecoin financial guardrails agentic AI needs. x.com 

UnitedHealth's model is a conflict of interest, since it owns both the insurer and the doctors and data, which makes it too dark to own. It has been accused of using algorithms to systematically deny care to the elderly and sick to lift profits; as both the largest US employer of doctors and an insurer, the patient loses. The assassination of its CEO showed deep hostility toward that system. A moat built on denying care is not worth owning. x.com 

Healthcare and biotech should see a massive capital rotation as aging populations seek to cheat death through cellular immunotherapy, nootropics and personalized medicine, and healthcare holds up in recessions while tech tanks. Eli Lilly is the best big-cap expression of the trade. Money should flow to concierge practices for a K-shaped economy and to new, expensive tailored drugs, while consumer outlets like CVS likely underperform. x.com  x.com  x.com